Atomoxetine in the treatment of attention deficit hyperactivity disorder

Expert Review of Neurotherapeutics

Volumn 4, Issue 4, 2004, Pages 601-611

  Kratochvil, Christopher J ^a   Vaughan, Brigette S ^a   Daughton, Joan M ^b   Mayfield Jorgensen, Michelle L ^b   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Creighton NE Jt Psychiat Resid P   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Norepinephrine; Psychopharmacology

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; FLUOXETINE; GUANFACINE; IMIPRAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ABUSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSURIA; ENURESIS; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MEDICAL DOCUMENTATION; NAUSEA; PILOT STUDY; PUBLICATION; REVIEW; SIDE EFFECT; SWEATING; THORAX PAIN; TIC; URINE RETENTION; VERTIGO; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; MENTAL DISORDERS; PROPYLAMINES;

EID: 3042783231     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.601     Document Type: Review

References (45)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington DC, USA (2000).
2. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adoles. Psychiatry 35, 409-432 (1996).
3. Spencer T, Biederman J, Wilens T et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 155, 693-695 (1998).
4. Greenhill L. Attention deficit hyperactivity disorder: the stimulants. Child. Adolesc. Psychiatric Clin. North Am. 4(1), 123-168 (1995).
5. Pliszka SR. Nonstimulant treatment of attention deficit hyperactivity disorder. CNS Spectrums 8(4), 253-258 (2003). Provides an excellent overview of nonstimulant treatments for attention deficit hyperactivity disorder.
6. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention deficit hyperactivity disorder. Child Adolesc. Psychiatry Clin. N. Am. 9(30), 605-646 (2000).
7. Conners CK, Casat CD, Gualtieri CT et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J. Am. Acad. Child. Adolesc. Psychiatry 35, 1314-1321 (1996).
8. Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry 158, 282-288 (2001).
9. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc. Psychiatric Clin. N. Am. 9(1), 77-97 (2000).
10. Dupaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda M, McGoey K. Parent ratings of attention deficit disorder symptoms: factor structure and normative data. J. Psychopathol. Beh. Assess. 20, 83-102 (1998).
11. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). MultiHealth Systems, NY, USA (1999).
12. Spencer T, Biederman J, Heiligenstein J et al. An open-label, dose ranging study of atomoxetine in children with attention deficit disorder. J. Child. Adolesc. Psychoparmacology 11, 251-265 (2001).
13. Kratochvil C, Heiligenstein J, Spencer T et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Amer. Acad. Child Adolesc. Psychiatry 41(7), 776-784 (2002). The only published study of atomoxetine and a stimulant.
14. Spencer JT, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention deficit hyperactivity disorder. J. Clin. Psychiatry 63, 1140-1147 (2002). Primary efficacy studies of atomoxetine in children.
15. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children with ADHD: a randomized, placebo-controlled dose response study. Pediatrics 108(5), 83 (2001).
16. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry 159, 1896-1901 (2002).
17. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol. Psychiatry 53, 112-120 (2003). Primary efficacy studies of atomoxetine in adults.
18. Biederman J, Spencer T. Attention deficit hyperactivity disorder as a noradrenergic disorder. Biol. Psychiatry 46, 1234-1242 (1999).
19. Plizska SR, McCracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J. Am. Acad. Child Adolesc. Psych. 35, 264-272 (1996).
20. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5), 699-711 (2002). Investigation of the mechanism of action of atomoxetine.
21. Stahl SM. Neurotransmission of cognition: part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J. Clin. Psychiatry 64(2), 110-111 (2003).
22. Eli Lilly & Co, Strattera®, Atomoxetine Package Insert. Eli Lilly & Co., Indianapolis, IN, USA (2003).
23. Ring BJ, Gillespie J, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 respeconsible for atomoxetine metabolism. Drug Metab. Dispos. 30, 319-323 (2002).
24. Belle DJ, Ernest S, Sauer J, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin. Pharmacol. 42, 1219-1227 (2002).
25. Michelson D, Kratochvil C, Newcorn J, Gao H. Atomoxetine for comorbid ADHD and affective symptoms. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
26. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, placebo, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Biol. Psychiatry 67, 149-156 (2002).
27. Heiligenstein JH, Spencer TJ, Faries DE et al. Efficacy of tomoxetine versus placebo in pediatric outpatients with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, NY, USA (2000).
28. Biederman J, Heiligenstein J, Faries D et al. Efficacy of atomoxetine versus placebo in school-age girls with attention deficit hyperactivity disorder. Pediatrics 6, 110 (2002).
29. Newcorn JH. Atomoxetine or three-times daily methylphenidate in children with ADHD. Scientific Proceedings of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
30. Kemner JE, Starr HL, Ciccone PE, Lynch JM. OROS® MPH provides greater ADHD symptom improvement than atomoxetine. Scientific Proceedings of the Annual Meeting of the American Psychiatric Association, NY, USA (2004).
31. Wigal S, McGough JJ, Posner K et al. Analog classroom study of amphetamine extended release and atomoxetine in youth with ADHD. Scientific Proceedings of the American Psychiatric Association, NY, USA (2004).
32. Allen AJ, Milton DF, Michelson D et al. Efficacy of atomoxetine treatment for adolescents with attention deficit hyperactivity disorder. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
33. Weiss M, Tannock R, Kratochvil C et al. Placebo controlled study of once-daily atomoxetine in the school setting. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
34. Kratochvil CJ, Milton D, Vaughan B, Burke W, Jones D. Atomoxetine in the treatment of young children with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
35. Kelsey D, Sumner C, Casat C et al. Once-daily atomoxetine for ADHD including evening and morning behavioral assessment. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
36. Michelson D. Optimizing response for ADHD residual symptoms after usual atomoxetine treatment. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
37. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Thomason C, Gelowitz DL. Effects of long-term atomoxetine treatment for young children with ADHD. Scientific Proceedings of the American Psychiatric Association, NY, USA (2004).
38. Wilens TE, Newcorn JH, Kratochvil CJ, Gelowitz DL, Thomason C Gao H. Longer-term treatment with atomoxetine in adolescents with ADHD. Scientific Proceedings of the American Psychiatric Association, NY, USA (2004).
39. Allen AJ, McCracken J, Sallee F et al. Improvement of ADHD by atomoxetine in children with tic disorders. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
40. Sumner C, Kelsey D, Sutton V et al. Atomoxetine versus placebo for treating pediatric nocturnal enuresis. Scientific Proceedings of the Annual Meeting of the American Academy of Pediatrics, LA, USA (2003).
41. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry, 63(Suppl. 12), 50-55 (2002). Summary of safety data from several atomoxetine pediatric trials.
42. Werniche JF, Adler L, Spencer T et al. Changes in the symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J. Clin. Psychopharmacol. 24(1), 30-35 (2004).
43. Wernicke JF, Faries D, Girod D et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26(10), 729-740 (2003).
44. Adler L, Spencer T, Sutton V, Jones D, Sumner CR. Dose and time response of atomoxetine use in adult ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, FL, USA (2003).
45. Adler L, Spencer T, Reimherr F, Michelson D, Jones D, Milton D. Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. Scientific Proceedings of the Annual Meeting of the American Psychiatric Association, CA, USA (2003).